The overall goal of this SPORE in lung cancer proposal is to translate recent advances in the understanding of the molecular pathogenesis of lung cancer into new methods to prevent, diagnose, and treat lung cancer. This SPORE is a logical development of the planning P20 SPORE in Lung Cancer awarded 3 years ago to UTSW. It developed out of 32 years of planning effort between UT Southwestern Medical Center (UTSW) and M.D. Anderson Cancer Center (MDACC), bringing together two major complementary strengths in lung cancer research in the areas of prevention, molecular pathogenesis, early detection, and development of novel therapies based on translational research. This SPORE consists of 5 inter-related projects and 3 supporting Cores. The projects in Lung Cancer are: 1. Identification of 3p Recessive Oncogenes; 2. Genetic Susceptibility: 3. Molecular Early Detection; 4. Chemoprevention in Former Smoker; 5. Mutant p53 Epitope Targeting. The Cores are: A. Administrative; B. Pathology and Tissue Resource; and C. Informatics. All of the scientific projects are: a) translational in nature; b) focus on human lung cancer; c) arose out of conjoint planning between UTSW and MDACC and involve investigators from both institutions as Co- investigators; d) interact with other projects; e) include basic and clinical investigators; and f) utilize Core resources. There is a substantial plan for innovative Developmental Projects, and a plan for Career Development that has already been productive from the UTSW P20 planning SPORE effort. There is a heavy emphasis on prevention, early detection and the development of novel therapies that could be applied to very early stage disease. In addition, the Developmental Program includes a project for the testing for genetic predisposition to nicotine dependency as a new approach to identifying persons at high risk of developing lung cancer. Achievement of the aims and objectives of this proposal will result in a major decrease in the incidence, morbidity and mortality of lung cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA070907-02
Application #
2517716
Study Section
Special Emphasis Panel (SRC (08))
Project Start
1996-09-30
Project End
1999-08-31
Budget Start
1997-09-05
Budget End
1998-08-31
Support Year
2
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Dallas
State
TX
Country
United States
Zip Code
75390
Song, Kai; Bi, Jia-Hao; Qiu, Zhe-Wei et al. (2018) A quantitative method for assessing smoke associated molecular damage in lung cancers. Transl Lung Cancer Res 7:439-449
Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221
He, Min; Liu, Shanshan; Gallolu Kankanamalage, Sachith et al. (2018) The Epithelial Sodium Channel (?ENaC) Is a Downstream Therapeutic Target of ASCL1 in Pulmonary Neuroendocrine Tumors. Transl Oncol 11:292-299
Parra, Edwin R; Villalobos, Pamela; Behrens, Carmen et al. (2018) Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J Immunother Cancer 6:48
Guo, Hou-Fu; Tsai, Chi-Lin; Terajima, Masahiko et al. (2018) Pro-metastatic collagen lysyl hydroxylase dimer assemblies stabilized by Fe2+-binding. Nat Commun 9:512
Meraz, Ismail M; Majidi, Mourad; Cao, Xiaobo et al. (2018) TUSC2 Immunogene Therapy Synergizes with Anti-PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras-Mutant Mouse Lung Cancer Models. Cancer Immunol Res 6:163-177
Zhang, Liren; Lin, Jing; Ye, Yuanqing et al. (2018) Serum MicroRNA-150 Predicts Prognosis for Early-Stage Non-Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene SRCIN1. Clin Pharmacol Ther 103:1061-1073
Bayo, Juan; Tran, Tram Anh; Wang, Lei et al. (2018) Jumonji Inhibitors Overcome Radioresistance in Cancer through Changes in H3K4 Methylation at Double-Strand Breaks. Cell Rep 25:1040-1050.e5
Ludlow, Andrew T; Wong, Mandy Sze; Robin, Jerome D et al. (2018) NOVA1 regulates hTERT splicing and cell growth in non-small cell lung cancer. Nat Commun 9:3112
Chen, Limo; Diao, Lixia; Yang, Yongbin et al. (2018) CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discov 8:1156-1175

Showing the most recent 10 out of 1059 publications